Bystolic Generic Name & Formulations
Mechanism of Action
Bystolic Dosage and Administration
Bystolic Boxed Warnings
CHF. Angina. Recent MI. Bronchospastic disease. Increased risk for hypoglycemia esp. in diabetics or those who are fasting (eg, surgery, not eating regularly, or vomiting). Hyperthyroidism. Severe renal impairment. Moderate hepatic impairment. Avoid abrupt cessation (taper over 1–2 weeks). Surgery. Peripheral vascular disease. Pheochromocytoma. Neonates (monitor). Pregnancy (esp. during 3rd trimester). Nursing mothers: not recommended.
Mean peak plasma concentrations occur ~1.5–4 hours post-dosing.
Plasma protein bound: ~98%.
Renal (38%), fecal (44%). Half-life: ~12 hours.
Bystolic Adverse Reactions
Bystolic Clinical Trials
Bystolic Patient Counseling